Recombinant Human HLA-B*15:02&B2M Monomer Protein (HEK293)，Avi & His

HLA-B*15:02 is a critical human leukocyte antigen associated with drug hypersensitivity reactions, particularly severe adverse reactions to carbamazepine, an anticonvulsant medication. The presence of this specific allele in individuals of Asian descent has been linked to an increased risk of developing Stevens-Johnson syndrome and toxic epidermal necrolysis, making its study essential for personalized medicine and pharmacogenomics. B2M, or beta-2-microglobulin, is a component of the major histocompatibility complex (MHC) class I molecules and plays a pivotal role in the immune response by stabilizing these complexes on the cell surface. Research involving the recombinant proteins of HLA-B*15:02 and B2M aims to elucidate the molecular mechanisms underlying drug hypersensitivity, improve diagnostic strategies, and develop potential therapeutic interventions. By examining the interaction between HLA-B*15:02 and B2M at a molecular level, scientists can gain insights into how specific genetic backgrounds can predispose individuals to severe drug reactions. This research is vital for enhancing drug safety, facilitating tailored treatment plans based on genetic profiling, and ultimately improving patient outcomes in populations at risk for adverse drug reactions.